Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab

Background: There is a lack of surrogate markers to predict the outcomes of nivolumab plus ipilimumab (Nivo-Ipi) for advanced renal cell carcinoma (RCC), but neutrophil to lymphocyte ratio (NLR) and tumour burden are promising candidates. This study investigated biological and radiological surrogate...

Полное описание

Библиографические подробности

Главные авторы:	M. Oshima, S. Washino, S. Shirotake, H. Takeshita, M. Inoue, Y. Miura, A. Nakayama, S. Nagamoto, T. Nakayama, K. Izumi, M. Oyama, S. Kawakami, K. Saito, Y. Matsuoka, T. Miyagawa
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2025-03-01
Серии:	ESMO Real World Data and Digital Oncology
Предметы:	neutrophil to lymphocyte ratio tumour burden renal cell carcinoma nivolumab ipilimumab
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2949820124000845
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!